Acknowledgement
This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP; Ministry of Science, ICT & Future Planning) (No. NRF-2018R1D1A1B07044595).
References
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C.: American Psychiatric Association; 2013.
- World Health Organization. Fact Sheets of Dementia [Internet]. Geneva: WHO; 2021 [cited 2022 Jul 7]. Available from: https://www.who.int/health-topics/dementia#tab=tab_1.
- Oriental Neuropsychiatry Editorial Committee of Korean Medicine schools. Oriental neuropsychiatry: revised ed. Gyeonggi: Jipmoondang; 2011. 332-41 p.
- Loew D. [Value of Ginkgo biloba in treatment of Alzheimer dementia]. Wien Med Wochenschr. 2002;152(15-16):418-22. German. https://doi.org/10.1046/j.1563-258X.2002.02065.x
- Xu SS, Gao ZX, Weng Z, Du ZM, Xu WA, Yang JS, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Acta Pharmacol Sin. 1995;16(5):391-5.
- Park SJ, Jung JM, Lee HE, Lee YW, Kim DH, Kim JM, et al. The memory ameliorating effects of INM-176, an ethanolic extract of Angelica gigas, against scopolamine- or Aβ(1-42)-induced cognitive dysfunction in mice. J Ethnopharmacol. 2012;143(2):611-20. https://doi.org/10.1016/j.jep.2012.07.019
- Choi SH, Park CH, Seo JH, Suh YH. Dehydroevodiamine.HCl protects neuron from cytotoxicity induced by Aβ or oxidative stress: its antioxidant. J Neurochem. 2002;81(s1):101-5.
- Lee JH, Lee EH, Jung EM, Kim DH, Kim SK, Park MH, et al. Perilla Frutescens extract protects against Scopolamine-induced memory deficits in mice. J Physiol Pathol Korean Med. 2021;35(3):97-103. https://doi.org/10.15188/kjopp.2021.06.35.3.97
- Gao YM, Wang XL, Deng YX, Reng JM, Shen XC, Guan ZZ, et al. Effect of Gastrodiae Rhizoma powder on prevention of dementia and oxidation resistance in mice. Chin J Exp Tradit Med Formulae. 2020;24:52-8.
- Bahramsoltani R, Rostamiasrabadi P, Shahpiri Z, Marques AM, Rahimi R, Farzaei MH. Aloysia citrodora Palau (Lemon verbena): a review of phytochemistry and pharmacology. J Ethnopharmacol. 2018;222:34-51. https://doi.org/10.1016/j.jep.2018.04.021
- Bilia AR, Giomi M, Innocenti M, Gallori S, Vincieri FF. HPLCDAD-ESI-MS analysis of the constituents of aqueous preparations of verbena and lemon verbena and evaluation of the antioxidant activity. J Pharm Biomed Anal. 2008;46(3):463-70. https://doi.org/10.1016/j.jpba.2007.11.007
- Schonbichler SA, Bittner LK, Pallua JD, Popp M, Abel G, Bonn GK, et al. Simultaneous quantification of verbenalin and verbascoside in Verbena officinalis by ATR-IR and NIR spectroscopy. J Pharm Biomed Anal. 2013;84:97-102. https://doi.org/10.1016/j.jpba.2013.04.038
- Cao L, Miao M, Qiao J, Bai M, Li R. The protective role of verbenalin in rat model of focal cerebral ischemia reperfusion. Saudi J Biol Sci. 2018;25(6):1170-7. https://doi.org/10.1016/j.sjbs.2017.10.005
- Makino Y, Kondo S, Nishimura Y, Tsukamoto Y, Huang ZL, Urade Y. Hastatoside and verbenalin are sleep-promoting components in Verbena officinalis. Sleep Biol Rhythms. 2009;7(3):211-7. https://doi.org/10.1111/j.1479-8425.2009.00405.x
- Ferdousi F, Kondo S, Sasaki K, Uchida Y, Ohkohchi N, Zheng YW, et al. Microarray analysis of verbenalin-treated human amniotic epithelial cells reveals therapeutic potential for Alzheimer's disease. Aging (Albany NY). 2020;12(6):5516-38. https://doi.org/10.18632/aging.102985
- Diehl MS, Willaby SL, Snyder RD. Comparison of the results of a modified miniscreen and the standard bacterial reverse mutation assays. Environ Mol Mutagen. 2000;36(1):72-7. https://doi.org/10.1002/1098-2280(2000)36:1<72::AID-EM10>3.0.CO;2-Y
- Maron DM, Ames BN. Revised methods for the Salmonella mutagenicity test. Mutat Res. 1983;113(3-4):173-215. https://doi.org/10.1016/0165-1161(83)90010-9
- Korean Neuropsychiatric Association. Textbook of neuropsychiatry. 3rd ed. Seoul: iMiS Company; 2019. 579-89 p.
- Kumar A, Singh A, Ekavali. A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67(2):195-203.
- Lane RF, Dacks PA, Shineman DW, Fillit HM. Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery. Alzheimers Res Ther. 2013;5(1):5.
- Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin. 2006;27(1):1-26. https://doi.org/10.1111/j.1745-7254.2006.00255.x
- Takata K, Kitamura Y, Saeki M, Terada M, Kagitani S, Kitamura R, et al. Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem. 2010;285(51):40180-91. https://doi.org/10.1074/jbc.M110.142356
- Sastre J, Millan A, Garcia de la Asuncion J, Pla R, Juan G, Pallardo FV, et al. A Ginkgo biloba extract (EGb 761) prevents mitochondrial aging by protecting against oxidative stress. Free Radic Biol Med. 1998;24(2):298-304.
- Wang BS, Wang H, Wei ZH, Song YY, Zhang L, Chen HZ. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis. J Neural Transm (Vienna). 2009;116(4):457-65. https://doi.org/10.1007/s00702-009-0189-x
- OECD. Test No. 471: bacterial reverse mutation test. Paris: OECD; 1997.